Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Influenza A (H7N9) virus vaccine
- Development stage
- Approved
- Lead developer
- Sinovac Biotech
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular, Intranasal
01
Overview
The influenza A (H7N9) virus vaccine is an investigational or stockpiled vaccine developed to protect against infection by the avian-origin H7N9 subtype of the influenza A virus. This subtype has caused several outbreaks in China since 2013, with a high case fatality rate and pandemic potential. The vaccines are typically inactivated or recombinant formulations designed to induce immune responses against the hemagglutinin and neuraminidase proteins of H7N9 viruses. While no H7N9 vaccines have been licensed for general human use as of 2024, several candidates have undergone preclinical and clinical development, showing protective benefits in animal models and robust antibody responses in humans[1][3][5]. Companies such as Sinovac have developed proprietary versions using established flu vaccine platforms[6]. These vaccines may be stockpiled for emergency use during outbreaks.
- Other names
- H7N9 vaccineH-7N9 vaccineH 7N9 vaccineavian influenza A(H7N9) vaccine
02
Targets
N9 NA (Influenza A neuraminidase N9)HA (Hemagglutinin)
Beyond the preview
Go deeper on Influenza A (H7N9) virus vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Influenza A (H7N9) virus vaccine.